Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 19/20 | 0.60 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.60 |
| ▸ | OXTR | P30559 | 6/20 | 0.60 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.60 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5677741 | 0.93 | AVPR1B (0.56) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5675622 | 0.93 | AVPR1B (0.54) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5674460 | 0.93 | AVPR1B (0.54) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5677829 | 0.92 | AVPR1B (0.54) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL2498626 | 0.92 | AVPR1B (0.54) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5678815 | 0.92 | AVPR1B (0.54) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5675252 | 0.92 | AVPR1B (0.54) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5677783 | 0.89 | AVPR1B (0.54) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5674060 | 0.87 | AVPR1B (0.49) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5674309 | 0.86 | AVPR1B (0.62) | AVPR1BAVPR1AOXTRAVPR2GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338590-B2 | Substituted oxindole derivatives and medicaments containing the same | ABBOTT GMBH & CO. KG (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20110257194-A1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | ABBOTT GMBH & CO. KG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-7951807-B2 | Substituted oxindol derivatives and medicaments containing the same | ABBOTT GMBH & CO. KG (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20090005397-A1 | Substituted Oxindol Derivatives and Medicaments Containing the Same | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-01-01 | — | — | US | disclosed |
| US-7119086-B2 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | disclosed |
| EP-1419150-B1 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005397-A1 | Substituted Oxindol Derivatives and Medicaments Containing the Same | OXTR, AVPR2, AVPR1B | AVPR1B 3/4885AVPR1A 4/4885OXTR 1/4885 |
| US-20110257194-A1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | OXTR, AVPR2, AVPR1B | AVPR1B 3/4885AVPR1A 4/4885OXTR 1/4885 |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | AVPR2, AVPR1A, AVPR1B | AVPR1B 3/4885AVPR1A 2/4885OXTR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.